FibroGen Inc
FibroGen Inc (FGEN) is a clinical-stage biopharmaceutical company best known for developing roxadustat, a hypoxia‑inducible factor (HIF) prolyl hydroxylase inhibitor for the treatment of anaemia in chronic kidney disease. Investors should know FibroGen is small‑cap (market capitalisation around $45M) and highly dependent on regulatory outcomes, partner agreements and the commercial performance of any approved therapies. Revenues and profitability have historically been volatile as clinical, legal and market events have influenced the company’s prospects. The stock tends to be sensitive to trial data, label decisions and changes in partner arrangements, so short‑term swings can be large. For longer‑term investors, the company’s pipeline and licensing deals may offer upside, but these come with typical biotech risks: clinical failure, regulatory setbacks and funding needs. This summary is educational and not personal financial advice—consider suitability, diversification and professional guidance before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding FibroGen's stock with a target price of $5.75, indicating potential growth.
Financial Health
FibroGen is showing strong revenue and profit margins, with positive cash flow indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FGEN
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and approvals can materially affect valuation, though outcomes are uncertain and performance may vary.
Small‑Cap Volatility
A market cap near $45M means the stock can swing widely on news; risk management and diversification are important.
Regulatory Impact
Approvals or restrictions in key markets shape commercial prospects, and regulatory shifts can change the investment thesis.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
